Fengzhen Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fengzhen Huang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Jiping Yi
Department of Neurology, Chenzhou No. 1 People's Hospital, Chenzhou, Hunan 423000, PR China
3 shared publicationsTieqiao Zhou
Department of Laboratory Medicine, the First People's Hospital of Chenzhou, Chenzhou, Hunan, 423000, P. R.China
2 shared publicationsXiaoxi Yao
Department of Neurology, the First People's Hospital of Chenzhou, Chenzhou, Hunan, 423000, P. R.China
2 shared publicationsChunrong Wang
Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China
1 shared publicationFei Zhou
Department of Neurology & Institute of Translational Medicine at University of South China, The First People's Hospital of Chenzhou, Chenzhou, Hunan 423000, PR China
1 shared publication- Gui-Hai Chen
Department of Neurology (Sleep Disorders), The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Chaohu, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 23 September 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (38) , e30792
Effects of schedule exercise therapy on chronic insomnia
Schedule exercise therapy (SET) is a novel nonpharmacological intervention for the treatment of chronic insomnia disorder (CID). The aim of this study was to explore the effects of SET on CID. Methods: One hundred and eighteen CID were recruited and randomized into medication (MED) or medication combined with SET (MSET) groups. Over 12 observational weeks, sleep and mood status were evaluated using the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), Self-rating Depression Scale (SDS), and Self-rating Anxiety Scale (SAS). At the end of the observational period, the rates of clinically effective hypnotic use were calculated. At 12 weeks, the PSQI progressively decreased for all subjects combined (P < .001) as well as ISI (P < .001), ESS (P < .001), SDS (P < .001), and SAS (P < .001). The decreases in PSQI (P < .05), ISI (P < .05), SDS (P < .01), and SAS (P < .05) in the MSET group were significantly larger than those in the MED group, but not the same as those in the ESS group (P > .05). At the trial endpoint, the clinically effective rate was significantly higher (P < .05) and the hypnotic usage rate was lower (P < .05) in the MSET group than in the MED group. SET may be an effective treatment for insomnia in patients with CID.
- 23 September 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (38) , e30792
Open AccessEffects of schedule exercise therapy on chronic insomnia
Schedule exercise therapy (SET) is a novel nonpharmacological intervention for the treatment of chronic insomnia disorder (CID). The aim of this study was to explore the effects of SET on CID. Methods: One hundred and eighteen CID were recruited and randomized into medication (MED) or medication combined with SET (MSET) groups. Over 12 observational weeks, sleep and mood status were evaluated using the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), Self-rating Depression Scale (SDS), and Self-rating Anxiety Scale (SAS). At the end of the observational period, the rates of clinically effective hypnotic use were calculated. At 12 weeks, the PSQI progressively decreased for all subjects combined (P < .001) as well as ISI (P < .001), ESS (P < .001), SDS (P < .001), and SAS (P < .001). The decreases in PSQI (P < .05), ISI (P < .05), SDS (P < .01), and SAS (P < .05) in the MSET group were significantly larger than those in the MED group, but not the same as those in the ESS group (P > .05). At the trial endpoint, the clinically effective rate was significantly higher (P < .05) and the hypnotic usage rate was lower (P < .05) in the MSET group than in the MED group. SET may be an effective treatment for insomnia in patients with CID.
- Open Access
- 10 July 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (28) , e21002
Case report: narcolepsy type 2 due to temporal lobe glioma
Rationale: The orexin projection system includes the lateral hypothalamus, reticular activating structure, and ventrolateral preoptic nucleus, and this system is related to the pathogenesis of narcolepsy. Here, we report a case of narcolepsy type 2 caused by hippocampal glioma of the right temporal lobe. Patient concerns: A 44-year-old male farmer complained of excessive daytime sleepiness (EDS) over the past 3 months and more. Interventions: The lesion of the right anteromedial temporal lobe was removed and its pathological examination was carried out. Outcomes: General examination showed no abnormalities of his heart, lungs, or abdomen. Neurological examination showed no positive sign. The blood routine and biochemical examination were normal. He scored 7 on the Pittsburg sleep quality index, 16 on the Epworth sleepiness scale, 52 on the self-rating anxiety scale, and 48 on the self-rating depression scale. The multiple sleep latency test data showed 2 periods of sleep-onset rapid eyes movement period across 4 successive tests; the average sleep latency was under 8 minutes, and the rapid eyes movement latency was under 7 minutes. Lesion of glioma in hippocampus area of the right anteromedial temporal lobe was confirmed through magnetic resonance imaging, magnetic resonance spectroscopy, and histological examination. After surgical removal of the glioma from the hippocampus area of the right anteromedial temporal lobe, the patient's EDS symptoms disappeared immediately. He scored 3 on the Epworth sleepiness scale. During our follow-up three months later, he remained well with no complications. Diagnosis: We diagnosed the patient with narcolepsy type 2 according to the 3rd Edition of International Classification of Sleep Disorders (ICSD-3). Conclusion: The patient suffered from EDS and was diagnosed with narcolepsy type 2. The narcolepsy type 2 was linked to glioma of the hippocampus area. The hippocampus might be another part of regulating the sleep-arousal pathway, and the glioma secretion might interact with the orexin projection system.
- 10 July 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (28) , e21002
Open AccessCase report: narcolepsy type 2 due to temporal lobe glioma
Rationale: The orexin projection system includes the lateral hypothalamus, reticular activating structure, and ventrolateral preoptic nucleus, and this system is related to the pathogenesis of narcolepsy. Here, we report a case of narcolepsy type 2 caused by hippocampal glioma of the right temporal lobe. Patient concerns: A 44-year-old male farmer complained of excessive daytime sleepiness (EDS) over the past 3 months and more. Interventions: The lesion of the right anteromedial temporal lobe was removed and its pathological examination was carried out. Outcomes: General examination showed no abnormalities of his heart, lungs, or abdomen. Neurological examination showed no positive sign. The blood routine and biochemical examination were normal. He scored 7 on the Pittsburg sleep quality index, 16 on the Epworth sleepiness scale, 52 on the self-rating anxiety scale, and 48 on the self-rating depression scale. The multiple sleep latency test data showed 2 periods of sleep-onset rapid eyes movement period across 4 successive tests; the average sleep latency was under 8 minutes, and the rapid eyes movement latency was under 7 minutes. Lesion of glioma in hippocampus area of the right anteromedial temporal lobe was confirmed through magnetic resonance imaging, magnetic resonance spectroscopy, and histological examination. After surgical removal of the glioma from the hippocampus area of the right anteromedial temporal lobe, the patient's EDS symptoms disappeared immediately. He scored 3 on the Epworth sleepiness scale. During our follow-up three months later, he remained well with no complications. Diagnosis: We diagnosed the patient with narcolepsy type 2 according to the 3rd Edition of International Classification of Sleep Disorders (ICSD-3). Conclusion: The patient suffered from EDS and was diagnosed with narcolepsy type 2. The narcolepsy type 2 was linked to glioma of the hippocampus area. The hippocampus might be another part of regulating the sleep-arousal pathway, and the glioma secretion might interact with the orexin projection system.
- 1 March 2019
- Published by Elsevier in Neuroscience Letters
- Vol. 696, 197-205
Upregulation of miR-496 decreases cerebral ischemia/reperfusion injury by negatively regulating BCL2L14
- 1 March 2019
- Published by Elsevier in Neuroscience Letters
- Vol. 696, 197-205
Upregulation of miR-496 decreases cerebral ischemia/reperfusion injury by negatively regulating BCL2L14
- Open Access
- 31 May 2017
- Published by Walter de Gruyter GmbH in Translational Neuroscience
- Vol. 8 (1) , 54-64
Toward understanding non-coding RNA roles in intracranial aneurysms and subarachnoid hemorrhage
Subarachnoid hemorrhage (SAH) is a common and frequently life-threatening cerebrovascular disease, which is mostly related with a ruptured intracranial aneurysm. Its complications include rebleeding, early brain injury, cerebral vasospasm, delayed cerebral ischemia, chronic hydrocephalus, and also non neurological problems. Non-coding RNAs (ncRNAs), comprising of microRNAs (miRNAs), small interfering RNAs (siRNAs) and long non-coding RNAs (lncRNAs), play an important role in intracranial aneurysms and SAH. Here, we review the non-coding RNAs expression profile and their related mechanisms in intracranial aneurysms and SAH. Moreover, we suggest that these non-coding RNAs function as novel molecular biomarkers to predict intracranial aneurysms and SAH, and may yield new therapies after SAH in the future.
- 31 May 2017
- Published by Walter de Gruyter GmbH in Translational Neuroscience
- Vol. 8 (1) , 54-64
Open AccessToward understanding non-coding RNA roles in intracranial aneurysms and subarachnoid hemorrhage
Subarachnoid hemorrhage (SAH) is a common and frequently life-threatening cerebrovascular disease, which is mostly related with a ruptured intracranial aneurysm. Its complications include rebleeding, early brain injury, cerebral vasospasm, delayed cerebral ischemia, chronic hydrocephalus, and also non neurological problems. Non-coding RNAs (ncRNAs), comprising of microRNAs (miRNAs), small interfering RNAs (siRNAs) and long non-coding RNAs (lncRNAs), play an important role in intracranial aneurysms and SAH. Here, we review the non-coding RNAs expression profile and their related mechanisms in intracranial aneurysms and SAH. Moreover, we suggest that these non-coding RNAs function as novel molecular biomarkers to predict intracranial aneurysms and SAH, and may yield new therapies after SAH in the future.
- Open Access
- 1 December 2015
- Published by Elsevier in Genomics Data
- Vol. 6, 108-109
miRNA profiling in autism spectrum disorder in China
- 1 December 2015
- Published by Elsevier in Genomics Data
- Vol. 6, 108-109
Open AccessmiRNA profiling in autism spectrum disorder in China